Abstract: The present invention provides methods for predicting whether a subject will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the predictive detection of neurological diseases in a subject. The methods and systems provided enable a quantitative assessment and theoretical predictions of neocortical amyloid loading or amyloid beta levels based on the measurement of biomarkers in biological fluids that will provide an indication of whether a subject is likely to develop a neurological disease, such as Alzheimer's disease (AD).

Abstract: The present invention relates generally to a method of modulating glutathione metabolism in the central nervous system of mammals and to agents for use therein. More particularly, the present invention relates to a method of up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursor molecules. The method of the present invention is particularly useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate central nervous system oxidation homeostasis including, but not limited to, schizophrenia.

Abstract: The present invention relates generally to a method of treating a psychiatric or neuropsychiatric condition in a mammal with a combination therapy. More particularly, the present invention relates to a combination therapy comprising an antipsychotic agent and a compound that increases levels of glutathione in the body.